# The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

> **NCT00419770** · PHASE2 · COMPLETED · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Mucormycosis

## Interventions

- **DRUG:** deferasirox
- **DRUG:** Placebo
- **DRUG:** Liposomal amphotericin B

## Key facts

- **NCT ID:** NCT00419770
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00419770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00419770, "The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00419770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*